サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771704

呼吸器合胞体ウイルスワクチン市場規模、シェア、動向分析レポート：タイプ別、技術別、対象人口別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.48円
呼吸器合胞体ウイルスワクチン市場規模、シェア、動向分析レポート：タイプ別、技術別、対象人口別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年06月17日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

呼吸器合胞体ウイルス（RSV）ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の呼吸器合胞体ウイルスワクチン市場規模は、2025年から2030年にかけて42.17%のCAGRを記録し、2030年までに283億9,000万米ドルに達する見込みです。

人口が高齢化し、COPD、喘息、糖尿病などの合併症が流行するにつれて、ワクチン接種のような予防措置に対する需要は増加の一途をたどっています。複数の年齢層でRSVワクチンが承認されたことで、対応可能な市場は大幅に拡大しました。さらに、公的な予防接種キャンペーンを含む政府支援の拡大が、ワクチン接種の普及と市場浸透を後押ししています。RSVが公衆衛生上の重大な脅威であるとの認識が世界的に高まっていることは、この分野への継続的な技術革新と投資の重要性を裏付けています。

市場成長を促進する主な要因は、公衆衛生当局によるワクチン推奨の拡大です。2025年4月、米国の予防接種実施諮問委員会（ACIP）は、重症RSV疾患のリスクが高い50～59歳の成人に対し、GSKのAREXVYを含むRSVワクチンを推奨することを決定しました。これには、喘息、慢性閉塞性肺疾患（COPD）、糖尿病、心臓病、長期介護施設入居者などの慢性疾患を持つ人が含まれます。この勧告は、2024年6月にACIPが行った、75歳以上のすべての成人、および基礎的な健康リスクのある60～74歳の成人へのワクチン接種を勧奨する投票に基づくものです。このような政策の拡大は、ワクチン接種率を向上させ、AREXVYのような製品の商業的可能性を高め、RSVワクチン市場をさらに活性化させる上で極めて重要です。

技術革新と製品の差別化も、RSVワクチン市場を形成する重要な力となっています。mRNAワクチンやアジュバントワクチンプラットフォームのブレークスルーは、有効性、安全性プロファイル、送達の利便性を向上させています。例えば、2024年5月に60歳以上の成人を対象に承認されたModerna社のmRNAワクチン「mRESVIA」は、同社にとって2番目のFDA承認mRNAワクチンであり、感染症予防におけるmRNA技術の勢いを示すものです。GSKのAREXVYは、アジュバント製剤を活用することで、高齢者、特に免疫力が低下している人の免疫反応を高めます。異なる人口セグメントに合わせた複数のワクチン選択肢が利用可能になることは、競争を支援すると同時に、アクセスを拡大し、RSVワクチンの有効性に対する市場の信頼を高めます。

官民両部門からの投資の増加により、臨床試験と規制当局による承認のペースが加速しています。ファイザー、Moderna、GSK、メルクなどの大手製薬会社は、大規模な第3相臨床試験を通じて、新たな適応症や年齢層を積極的に追求しています。ファイザーは、RSVワクチンABRYSVOの若年層への拡大を続けています。このような開発により、競合の激化、製品革新の改善、長期的なコスト低下が期待され、これは特に新興経済諸国において長期的な市場成長を維持するために極めて重要です。

さらに、世界の保健機関とのパートナーシップや段階的な価格戦略は、中低所得国全体でRSVワクチンへのアクセスを拡大する上で鍵となるでしょう。気候変動や世界の流動性によりRSVの季節性や伝播パターンが変化する中、統合的なサーベイランスや対応可能なワクチン接種政策がますます重要になるでしょう。推奨の拡大と強力な技術革新のパイプラインにより、RSVワクチン市場は継続的な成長と公衆衛生への影響をもたらす態勢が整っています。

呼吸器合胞体ウイルスワクチン市場レポート・ハイライト

  • 2024年には、主にモノクローナル抗体（mAb）療法の進歩に牽引され、受動免疫が75.02%の市場シェアで市場をリードしました。
  • モノクローナル抗体（mAb）セグメントは2024年に圧倒的な市場シェアを確保しました。mAbは即時受動免疫を提供するため、新生児や免疫不全患者などのハイリスク集団を保護するのに理想的です。
  • 乳幼児と小児は、高い疾病負担と最近の予防的ブレークスルーにより、2024年には75.02%の最大市場シェアを占めました。RSVは世界的に乳幼児の入院の主な原因であり、効果的な予防対策への緊急な需要が促されています。
  • 病院と小売薬局が2024年に53.68%のシェアで市場を独占すると予想され、その燃料は需要の高まり、ワクチン入手のしやすさ、予防接種プログラムの拡大です。
  • 北米は、RSV感染症の高い有病率と先進的なヘルスケアインフラを背景に、世界のRSVワクチン市場で大きなシェアを占めています。
  • 世界のRSVワクチン市場は競争が激しく、AstraZeneca、Sanofi、GSK、Pfizer、Moderna、Icosavax、Meissa Vaccines、Codagenix、Blue Lake Biotechnology、Merckなどの主要企業がワクチン強化に注力しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 RSV（呼吸器合胞体ウイルス）ワクチン市場の変数、動向、範囲

  • 市場イントロダクション/系統展望
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 呼吸器合胞体ウイルス（RSV）ワクチン市場分析ツール
    • ポーター分析
    • PESTEL分析

第4章 市場：タイプ推定・動向分析

  • セグメントダッシュボード
  • 市場：タイプ変動分析、2024年および2030年
  • 受動免疫
  • 予防ワクチン

第5章 市場：技術推定・動向分析

  • セグメントダッシュボード
  • 市場：技術変動分析、2024年および2030年
  • モノクローナル抗体
  • 組み換えタンパク質+ アジュバント
  • mRNAベースのワクチン
  • ウイルス様粒子（VLP）

第6章 市場：対象人口推定・動向分析

  • セグメントダッシュボード
  • 市場：ターゲット人口変動分析、2024年および2030年
  • 大人
  • 乳幼児

第7章 市場：流通チャネルの推定・動向分析

  • セグメントダッシュボード
  • 市場：流通チャネル変動分析、2024年および2030年
  • 病院および薬局
  • 政府サプライヤー
  • その他

第8章 市場：地域推定・動向分析

  • 市場シェア、地域別、2024年および2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • AstraZeneca
    • Sanofi
    • GSK
    • Pfizer Inc.
    • Moderna
    • Icosavax
    • Meissa Vaccines
    • Codagenix
    • Blue Lake Biotechnology
    • Merck &Co., Inc.
図表

List of Tables

  • Table 1. List of abbreviation
  • Table 2. Global RSV (Respiratory Syncytial Virus) vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 3. Global RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 5. Global RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 6. Global RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 10. North America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 11. North America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 13. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 14. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 15. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Canada RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 17. Canada RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 18. Canada RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 19. Canada RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 21. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 23. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Europe RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 25. Europe RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 26. Europe RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 27. Europe RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 28. Europe RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. UK RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 30. UK RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 31. UK RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 32. UK RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Germany RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 34. Germany RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 35. Germany RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 36. Germany RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. France RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 38. France RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 39. France RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 40. France RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Italy RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 42. Italy RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Italy RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 44. Italy RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Spain RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 46. Spain RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 47. Spain RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 48. Spain RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 50. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 51. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 52. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 54. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 55. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 56. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Norway RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 58. Norway RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 59. Norway RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 60. Norway RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Japan RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 67. Japan RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 68. Japan RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 69. Japan RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. China RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 71. China RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 72. China RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 73. China RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. India RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 75. India RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 76. India RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 77. India RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78. Australia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 79. Australia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 80. Australia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 81. Australia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 83. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 84. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 85. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 87. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 89. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 91. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 92. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 93. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 94. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 96. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 97. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 98. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 100. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 101. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 102. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103. MEA RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 104. MEA RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 105. MEA RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 106. MEA RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 107. MEA RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 109. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 110. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 111. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116. UAE RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 117. UAE RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 118. UAE RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 119. UAE RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 121. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 122. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 123. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RSV (Respiratory Syncytial Virus) vaccines market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 RSV (Respiratory Syncytial Virus) vaccines market: Product outlook key takeaways
  • Fig. 20 RSV (Respiratory Syncytial Virus) vaccines market: Type movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 RSV (Respiratory Syncytial Virus) vaccines market: Technology outlook key takeaways
  • Fig. 24 RSV (Respiratory Syncytial Virus) vaccines market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Recombinant Protein + Adjuvant market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population outlook key takeaways
  • Fig. 29 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population movement analysis
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infants and children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel outlook key takeaways
  • Fig. 33 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel movement analysis
  • Fig. 34 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Spain RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Market participant categorization
  • Fig. 78 RSV (Respiratory Syncytial Virus) vaccines market position analysis, 2024
  • Fig. 79 Strategic framework
目次
Product Code: GVR-4-68040-625-1

RSV Vaccines Market Growth & Trends:

The global respiratory syncytial virusvaccines market size is expected to reach USD 28.39 billion by 2030, registering a CAGR of 42.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. As populations age and comorbidities such as COPD, asthma, and diabetes become more prevalent, the demand for preventive measures like vaccination continues to rise. Regulatory approvals of RSV vaccines across multiple age groups have significantly expanded the addressable market. Furthermore, growing government support, including public immunization campaigns, has helped boost vaccination uptake and market penetration. The increasing global recognition of RSV as a serious public health threat underlines the importance of continued innovation and investment in this sector.

A key factor propelling market growth is the expansion of vaccine recommendations by public health authorities. In April 2025, the U.S. Advisory Committee on Immunization Practices (ACIP) voted to recommend RSV vaccines, including GSK's AREXVY, for adults aged 50-59 who are at elevated risk of severe RSV disease. This includes individuals with chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, heart disease, and those residing in long-term care facilities. This recommendation builds upon ACIP's earlier vote in June 2024 to advise vaccination for all adults aged 75 and older, and for those aged 60-74 with underlying health risks. These policy expansions are critical in driving vaccine coverage and boosting the commercial viability of products like AREXVY, further energizing the RSV vaccine market.

Technological innovation and product differentiation are also vital forces shaping the RSV vaccine landscape. Breakthroughs in mRNA and adjuvanted vaccine platforms have improved efficacy, safety profiles, and delivery convenience. For example, Moderna's mRESVIA, approved in May 2024 for adults aged 60 and older, represents the company's second FDA-approved mRNA vaccine and highlights the momentum of mRNA technologies in infectious disease prevention. GSK's AREXVY leverages an adjuvanted formulation to enhance immune response in older adults, especially those with weakened immune systems. The availability of multiple vaccine options tailored to different population segments supports competition while broadening access and boosting market confidence in RSV vaccine efficacy.

Increased investments from both public and private sectors are accelerating the pace of clinical trials and regulatory approvals. Major pharmaceutical companies such as Pfizer, Moderna, GSK, and Merck are actively pursuing new indications and age groups through extensive Phase 3 trials. Pfizer continues to expand its RSV vaccine ABRYSVO into younger adult age groups. These developments are expected to intensify competition, improve product innovation, and lower costs over time, which is crucial for sustaining long-term market growth, particularly in emerging economies.

Additionally, partnerships with global health organizations and tiered pricing strategies will be key in expanding RSV vaccine access across low- and middle-income countries. As climate change and global mobility contribute to changes in RSV seasonality and transmission patterns, integrated surveillance and responsive vaccination policies will be increasingly important. With expanding recommendations and a strong innovation pipeline, the RSV vaccine market is poised for continued growth and public health impact.

Respiratory Syncytial Virus Vaccines Market Report Highlights:

  • In 2024, passive immunization led the market with a market share of 75.02%, primarily driven by advancements in monoclonal antibody (mAb) therapies.
  • The monoclonal antibodies (mAbs) segment secured the dominant market share in 2024. mAbs offer immediate passive immunity, making them ideal for protecting high-risk populations such as newborns and immunocompromised individuals.
  • The infants and children held the largest market share of 75.02% in 2024, due to the high disease burden and recent preventive breakthroughs. RSV is the leading cause of hospitalization in infants globally, prompting urgent demand for effective protective measures.
  • Hospital & retail pharmacies are expected to dominate the market in 2024 with share of 53.68% fueled by rising demand, vaccine accessibility, and expanding immunization programs.
  • North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure.
  • The global RSV vaccines market is highly competitive, with key players such as AstraZeneca, Sanofi, GSK, Pfizer, Moderna, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, and Merck, focusing on enhancing the vaccine.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. RSV (Respiratory Syncytial Virus) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. RSV (Respiratory Syncytial Virus) Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Passive Immunization
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Preventive Vaccines
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Recombinant Protein + Adjuvant
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. mRNA-Based Vaccine
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Virus-Like Particle (VLP)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Adults
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Infants and children
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital & Retail Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Government Suppliers
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. RSV (Respiratory Syncytial Virus) Vaccines Market: Regional Estimates & Trend Analysis

  • 8.1. RSV (Respiratory Syncytial Virus) Vaccines Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Moderna
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Icosavax
      • 9.4.6.1. Financial Performance
      • 9.4.6.2. Product Benchmarking
      • 9.4.6.3. Recent Developments/ Strategic Initiatives
    • 9.4.7. Meissa Vaccines
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Codagenix
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Blue Lake Biotechnology
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Merck & Co., Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives